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Abstract
Background: Dementia is more common in older than in younger people, and as a result of the ageing of the
population in developed countries, it is becoming more prevalent. Drug treatments for dementia are limited, and
the main support offered to people with dementia and their families is generally services to mitigate against loss
of function. Physical exercise is a candidate non-pharmacological treatment for dementia.
Methods/Design: DAPA is a randomised controlled trial funded by the National Institute for Health Research Health
Technology Assessment programme to estimate the effect of a 4-month, moderate- to hard-intensity exercise training
programme and subsequent advice to remain active, on cognition (primary outcome) at 12 months in people with
mild to moderate dementia. Community-dwelling participants (with their carers where possible), who are able to walk
3 metres without human assistance, able to undertake an exercise programme and do not have any unstable or
terminal illness are recruited. Participants are then randomised by an independent statistician using a computerised
random number generator to usual care or exercise at a 2:1 ratio in favour of exercise. The exercise intervention
comprises 29, 1-hour-long exercise classes, run twice weekly at suitable venues such as leisure centres, which include
aerobic exercise (on static bikes) and resistance exercise (using weights). Goals for independent exercise are set while
the classes are still running, and supported thereafter with phone calls.
The primary outcome is measured using ADAS-cog. Secondary outcome measures include behavioural symptoms,
functional ability, quality of life and carer burden. Primary and secondary outcomes will be measured at baseline and
at 6 and 12 months after randomisation, by researchers masked to participant randomisation in the participants’ own
homes. An economic evaluation will be carried out in parallel to the RCT, as will a qualitative study capturing the
experiences of participants, carers and staff delivering the intervention.
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Discussion: The DAPA study will be the first large, randomised trial of the cognitive effects of exercise on people with
dementia. The intervention is designed to be capable of being delivered within the constraints of NHS service provision,
and the economic evaluation will allow assessment of its cost-effectiveness.
Trial registration: DAPA was registered with the ISRCTN database on 29 July 2011, registration number
ISRCTN32612072.
Keywords: Dementia, Exercise, Randomised controlled trial
Background
Dementia is a syndrome characterised by acquired,
progressive deterioration in memory, general cognitive
function, self-care and personality. Probable dementia
according to the Diagnostic and Statistical Manual,
4th Edition (DSM IV) criteria is defined by:
(a)Memory impairment with cognitive disturbance in
at least one of the following domains: aphasia
(language impairment), apraxia (motor impairment),
agnosia (impairment of object recognition) or
executive functioning (planning, sequencing,
abstracting); and
(b)Functional decline: increasing impairment in functional
ability (social, occupational, personal/self-care) related
to cognitive deficits.
About 60 % of cases of dementia in developed coun-
tries are caused by Alzheimer’s disease, and about 20 %
are vascular dementia [1], while mixed Alzheimer/vascu-
lar dementia and dementia with Lewy bodies are the
other common causes. Dementia affects older people to
a much greater extent than younger people. The preva-
lence of dementia in developed countries is under 1 %
for people aged 65–69 years, rising to about 35 % in
people aged 95–99 years, and prevalence doubles in
successive 5-year age groups within the age range 65–99
years [2]. Prevalence is similar in men and women [2].
Treatments for dementia recommended by the National
Institute for Health and Care Excellence (NICE) [3] are
cholinesterase inhibitors (donepezil, galantamine and
rivastigmine), but only for mild to moderate Alzheimer’s
disease (not for vascular dementia). Memantine is
supported by NICE for limited use in moderate to severe
dementia, or in patients unable to tolerate cholinesterase
inhibitors [3]. Many people with mild to moderate demen-
tia and their families require additional services, mainly to
mitigate functional loss, such as carer training, home
carers, day care, respite admissions, sitting services and
carer support services.
Physical exercise is a candidate non-pharmacological
treatment for dementia. The most recent Cochrane
review of physical activity for people with dementia [4]
included 17 studies, nine of which assessed the effect of
exercise on cognition. The authors concluded that there
was encouraging evidence for the effectiveness of
physical activity in improving cognition and other
outcomes in people with dementia. However, these
studies suffer from having small sample sizes, short-
term follow-up and other methodological problems.
There is a need for large, randomised trials of exercise
in people with dementia.
Objectives
The primary objective is to undertake a definitive rando-
mised controlled trial (RCT) to estimate the effect of a
4-month, moderate- to hard-intensity exercise training
programme and subsequent advice to remain active on
(1) global cognition (primary outcome) and (2) function,
behaviour, health-related quality of life and carer burden
(secondary outcomes) in community-dwelling people
with mild to moderate dementia.
Other objectives are to conduct a parallel economic
evaluation from a National Health Service (NHS) and
personal social services perspective and from a societal per-
spective, with a view to estimating the cost-effectiveness of
the programme, and to complete a qualitative study along-
side the trial.
Methods/Design
Trial design
We have designed a multi-centred, randomised parallel
group trial with an economic evaluation to compare a 4-
month, supervised, moderate- to hard-intensity exercise
training regime with follow-on behavioural support for
long-term physical activity change, in comparison to best
practice usual care. The study design is outlined in Fig. 1.
Participants are randomised in unbalanced allocation prior
to entry into the study, then followed up for 12 months.
Carers are recruited to provide an additional data set. Par-
ticipants, carers, and treating therapists not are masked,
but all baseline and follow-up assessments are undertaken
by masked assessors. The analysis will be undertaken by
statisticians who are masked to the allocation code. More
details are available in the latest version of the Dementia
and Physical Activity (DAPA) protocol, version 2.0, dated
7 July 2014.
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Study oversight
The overall supervision of the trial will be carried out by
the Trial Steering Committee (TSC). This committee
comprises the Chief Investigator, trial manager, statisti-
cian, and four independent members (including the
committee chair). The TSC will monitor trial progress
Fig. 1 Flowchart of study design
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and conduct, and provide expert advice. In addition, an
independent Data Monitoring and Ethics committee
(DMEC) comprising three independent members, will
review the progress of the trial and review safety data as
it emerges. The DMEC will consist of independent
experts with relevant clinical research and statistical
experience. During the period of recruitment into the
trial, reports of the accumulating data will be supplied,
in strict confidence, to the DMEC, along with any other
reports that the committee may request. There is no
formal interim analysis proposed.
All substantial amendments to the protocol will be
submitted to the ethics committee for approval. All
non-substantial amendments will be submitted to the
ethics committee for notification purposes. In addition,
all substantial and non-substantial amendments to the
protocol will be notified on a regular basis to the Trial
Steering Committee, Data Monitoring Committee and
Trial Management Committee. Where appropriate, and
of operational purpose, the amendments will be noti-
fied to the Principal Investigators and other relevant
trial and clinical staff. Trial registers will be informed
of substantial amendments.
The trial sponsor is the University of Warwick. The
sponsor has no role in the trial design; collection, manage-
ment, analysis or interpretation of data; writing of reports
and submission for publication.
Ethics, ethical issues and arrangements for consent
Ethics approval for the DAPA trial was given by the
National Research Ethics Committee (South West –
Frenchay) REC number 11/SW/0232, on 19 January
2012. People with mild to moderate dementia may lack
the necessary mental capacity to provide fully informed
consent. All potential participants are assessed carefully
for their capacity to consent by trained healthcare pro-
fessionals. Where potential participants are assessed as
having capacity, informed consent is obtained from the
individual. Where potential participants are assessed as
lacking capacity, in compliance with the Mental Capacity
Act 2005 and best practice, agreement to participate is
still sought from these individuals. In addition, we obtain
advice from the primary carer/personal consultee, on
whether the person who lacks capacity should take part
in the project, and what their past and present wishes
and feelings would have been about taking part. For
those participants unable to give informed consent, and
for whom no personal consultee is available, we will
seek a nominated consultee (e.g. healthcare profes-
sional) who is well-placed and prepared to act on behalf
of the potential participant. Where a potential partici-
pant lacks capacity to provide informed consent, and a
nominated consultee cannot be found, that person will
not be recruited. Consent will be obtained from carers
for their own participation in data collection and quali-
tative interviews.
Setting
We will recruit community-dwelling people with mild to
moderate dementia and, where available, their carers. Po-
tential participants will be identified from a number of
sources: secondary and primary care clinics, registers of
people with dementia who have expressed an interest in
participating in research (called research interested lists)
and community dementia resources e.g. dementia cafes.
We aim to recruit a sample to provide estimates of
effect of the exercise intervention that are generalizable
to the range of settings and populations served by NHS
England. In terms of geographical spread, we will
include both urban and more rural areas. NHS organisa-
tions included are: Sandwell and West Birmingham
Clinical Commissioning Group (CCG), Telford CCG,
Nene CCG, West Leicestershire CCG, Coventry and
Warwickshire Partnership Trust, Oxford Health NHS
Foundation Trust, Berkshire Healthcare NHS Foundation
Trust, Worcestershire Health and Care Foundation Trust,
Northamptonshire Healthcare NHS Foundation Trust,
Leicestershire Partnership NHS Trust, Solent NHS Trust,
Royal Devon and Exeter NHS Foundation Trust, Greater
Manchester West Mental Health NHS Foundation Trust,
Black Country Partnership NHS Foundation Trust,
Coventry and Rugby CCG, South Warwickshire CCG,
Warwickshire North CCG, South Worcestershire
CCG, Redditch and Bromsgrove CCG, 2gether NHS
Foundation Trust and North East London NHS
Foundation Trust.
Approach
Potential participants will be approached from four
sources:
1. NHS secondary care memory clinics and services.
Research assistants will identify potential
participants using electronic or case record searches
to screen for eligibility. The lists are reviewed by a
clinician involved in the clinical care of the
participant, and exclusions checked. Potential
participants and their carers will then be approached
either face-to-face at clinic or by letter. In either in-
stance, the initial approach is made by the clinician
known to the potential participant, and independent
of the research team.
2. General Practice registers of people with dementia:
GP practices will search their registers of patients to
identify people with a diagnostic code for dementia.
In most practices this will be done by a search of
databases using read codes or Quality Outcomes
Framework codes. Each GP practice lead will
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approve the final list of names, and invitation letters
will be sent.
3. Research network Participant Interested Databases
(e.g. the Dementia and Neurodegenerative Diseases
Network (DeNDRoN); Join Dementia Research): the
Department of Health in the UK has funded a
number of networks and projects to enable people
with dementia to register their interest in
participating in research and to enable a rapid and
simple approach. Potential participants will be
identified by a Research Nurse from these databases.
Participants deemed as meeting the inclusion criteria
will be contacted by telephone to explain the study,
and if potentially eligible, sent an invitation letter.
4. Other dementia resources (e.g. Alzheimer cafes): we
will approach community-based dementia resources
directly to determine if they are willing to approach
potential participants. If agreed by the service pro-
viders, a researcher from the team will visit the centres
and explain the study to potential participants and
their carers. If any participants/carers are interested,
the researcher will assess their potential eligibility and
contact their healthcare provider to confirm eligibility.
Regardless of the method of approach, once a participant
has confirmed their willingness to participate they will be
contacted by a member of the recruitment team (a regis-
tered nurse or allied health professional) to further assess
eligibility and explain the study. All participants will receive
written and verbal information, and be given a minimum
of 48 h to decide whether they wish to join the trial. We
will visit all the participants in their own homes to confirm
consent in writing, undertake a baseline assessment and
then register and randomise the participant.
Inclusion and exclusion criteria
To be included participants must:
1. Have probable dementia according to DSM IV;
2. Have probable mild to moderate dementia (>10 on
the standardised Mini-Mental State Examination
(sMMSE) [5]);
3. Be able to participate in a structured exercise
programme determined by:
(a)be able to sit in a chair, and walk 10 ft without
human assistance;
(b)have no unstable medical conditions, e.g. unstable
angina, or acute or terminal illness;
4. Live in the community, alone or with a friend,
relative or carer, or in sheltered accommodation.
Baseline assessment
The standardised Mini-Mental State Examination
(sMMSE) [5] will be carried out immediately after
consent is obtained, as a screen to ensure that the
participant is eligible. We will then collect demographic
and descriptive data on the participants including age,
gender, marital status, ethnicity, educational attainment,
employment status, and type of dementia (vascular,
Alzheimer’s or mixed). In addition, we will collect the
pre-randomisation (baseline) values for the outcomes
to be collected during the follow-up phase of the trial
(see Table 1).
Randomisation/masking
The unit of randomisation is the individual patient. Ran-
domisation will be stratified by site and dementia severity
(moderate or mild). Dementia severity is defined as
moderate for those with an sMMSE >10 but <20, and as
mild dementia for those with an sMMSE ≥20. Participants
will be randomised to (1) usual practice care, or (2) usual
practice care plus exercise intervention. Randomisation
will be 2:1 in favour of the intervention group, to allow ex-
ercise groups to be assembled in a shorter period of time.
As a result, participants are less likely to withdraw between
Table 1 Outcome measures taken at baseline, 6-month and 12-month time points
Domain Measure Data supplied by
Primary Cognition Alzheimer’s Disease Assessment Scale-cognitive
subscale (ADAS-cog) [6]
Participant (rating self)
Secondary Function Bristol Activities of Daily Living scale [8] Carer (rating participant)
Health-related quality of life Euro-QoL (EQ-5D) [10] Participant (rating self)
Euro-Qol (EQ-5D) Carer (rating self)
Euro-Qol (EQ-5D) proxy Carer (rating participant)
Dementia quality of life Quality of Life in Alzheimer’s Disease (QoL-AD) [9] Participant (rating self)
Quality of Life in Alzheimer’s Disease (QoL-AD) proxy Carer (rating participant)
Behavioural symptoms Neuropsychiatric Inventory (NPI) [11] Carer (rating participant)
Carer burden Zarit Burden Interview (ZBI) [12] Carer (rating self)
Health and social care usage to inform
the health economics analysis
Client Services Receipt Inventory (CSRI) [13] Participant with carer where
possible (rating participant)
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randomisation and the exercise classes commencing, are
not kept waiting excessively long periods between random-
isation and treatment provision, and the baseline measures
are made close to the exercise classes commencing.
The random allocation sequence will be generated by an
independent statistician using a computerised random
number generator, and implemented by a central telephone
registration and randomisation service at the Warwick
Clinical Trials Unit (WCTU).
Research clinicians (registered nurses or allied health
professionals) will register participants after obtaining
consent, confirming eligibility and undertaking a baseline
assessment. Once registered, the allocation will be gener-
ated, and the WCTU DAPA trial team will inform the
participant of their allocation and make arrangements for
treatment referral. Neither intervention providers nor
participants can be masked to treatment allocation. If a
research clinician becomes unmasked then follow-up
assessments will be conducted by different research
workers, and all study personnel involved with data entry,
follow-up assessments, management and analysis will be
masked until the final analysis is complete.
Choice of outcome measures
The primary outcome will be the global cognition score of
the Alzheimer’s Disease Assessment Scale-cognitive sub-
scale (ADAS-cog) [6], measured at 12-month follow-up.
This instrument has 11 standard items, and additionally
the maze and number cancellation optional items, which
will be reported separately. It takes about 30–40 minutes
to administer. The score ranges from 0 to 70, with higher
scores indicating greater impairment. Cognitive deficits
are central to dementia and widely understood as the
most important treatment target. In the original study
protocol, standardised Mini-Mental State Examination
(sMMSE) [5] was the measure of cognition used. It was
replaced by ADAS-cog on the recommendation of the
TSC and DMEC because the latter is widely considered
the gold standard primary outcome in treatment trials for
dementia, with relatively well-established treatment effect
sizes [7], and has superior sensitivity to change and hence
is a more efficient instrument from the point of view of
experimental design.
Secondary outcomes have been chosen to reflect the
broad impact of dementia: on function, on behaviour, on
quality of life, on economic costs, and on the carer. Where
possible, we have chosen instruments which are dementia-
specific, well-validated and not excessively burdensome.
Secondary outcomes are detailed in Table 1.
We will use the Bristol Activities of Daily Living scale
(BADL) [8]. This carer-rated instrument is dementia-
specific and covers 20 activities of daily living. It is sensi-
tive to change and widely used in clinical trials. Quality
of life is widely considered important in dementia. We
will collect data using the Quality of Life in Alzheimer’s
Disease (QoL-AD) [9], a 13-item dementia-specific scale
which can be completed by a carer or participant (both
will be collected during the DAPA trial). We will also
collect the EuroQol EQ-5D [10], a 5-dimension generic
(i.e. not dementia-specific) measure of health-related
quality of life. This will be collected from both the
participant’s and the carer’s perspective. EuroQol EQ-5D
allows a calculation of health utilities for application in
economic evaluations.
We will use the Neuropsychiatric Inventory (NPI) [11].
This scale assesses 12 dimensions of possible behavioural
disturbance in dementia, including important predictors
of care breakdown like depression and agitation, using a
screening strategy to save time. We will collect data using
the Zarit Burden Inventory (ZBI) [12]. This short scale is
the most commonly used dementia-specific carer burden
tool. We will collect cost data using the Client Services
Receipt Inventory (CSRI) [13]. This detailed questionnaire
is used with a carer and covers all social, health care,
medication use and out of pocket expenses. It will be
adapted for DAPA.
For carers, we will record carer age, gender, ethnicity,
and details about the relationship they have with the
person with dementia and how much care they provide.
They will be asked to complete the Zarit Burden Inter-
view [12], which measures carer burden, and the Euro-
Qol EQ-5D [10] measuring their own health-related
quality of life. They will be asked to complete several
measures regarding the person with dementia whom
they care for: Bristol Activities of Daily Living (BADL)
scale [8], Proxy QoL-AD [9], the number of falls and
fractures the person has had, and the NPI [11].
Additionally, at the 6-month and 12-month follow-up
interviews, the carer will be asked “How much benefit
have you gained from being in the DAPA trial?” and
“How much has the dementia of the person you care for
changed in the past 6 months?” The CSRI is usually
asked of the carer about the participant at this time
point, but a person with no carer can give as much
information as they are able.
These outcomes are all among those recommended by
a consensus recommendation of outcome scales for
non-drug interventional studies in dementia [14].
Training and quality assurance in the research protocol
We will train all staff involved in recruitment and baseline
assessments during a 1-day face-to-face training session,
supplemented by a detailed operational Recruitment
Manual. The ADAS-cog is a measure which needs initial
training, shadowing and practice over time to become
proficient. Potential recruitment staff have differing ex-
perience of using this measure so training will be adapted
to accommodate this. Those with a working knowledge of
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the measure will attend a data collection training day
which will include: rating a video of an ADAS-cog admin-
istration on a simulated patient, discussion around indi-
vidual items and performing an ADAS-cog simulation
with a trainer to assess practical competency. Based on
competency, we will decide whether the rater requires
further shadowing and training. Inexperienced raters will
have an initial introduction to the measure, shadow expe-
rienced raters and practice until they are ready to under-
take the training day. They will also be required to pass a
competency test. This day will also include training for
the sMMSE screening tool and other outcome measures.
Quality control (QC) will include the observation of at
least one baseline home visit per researcher to ensure
recruitment and data collection processes are followed
correctly. All questionnaire data will be sent to WCTU,
where it will be checked on receipt for discrepancies and
errors. We will provide feedback to the research nurses
and therapists by email to improve standards. Further
QC visits will be used to check source data collection
and completion of paperwork as necessary.
Study interventions
Usual care
All participants will receive usual care in compliance
with the recommendation of the NICE clinical guidance,
comprising information provision and limited social
support. We recognise that the usual care interventions
are variable across the country, and hence we will
stratify the randomisation within centre to ensure these
effects are randomly distributed. To account for any
such differences in the control arm, the analyses will
adjust for “centre” as a covariate. There will be no limit
on co-interventions during the trial, medications and
other treatments may be initiated, continued or discon-
tinued at the discretion of the clinical team responsible
for the care of the participants. We will collect data on
treatments provided to both arms of the trial during the
follow-up period, and describe these in the study
reports. Exercise is not currently part of recommended
usual care for people with dementia, but each study
participant (in both the control and intervention groups)
will be given one of two information sheets produced by
the Department of Health, appropriate to their age
group. The information sheets recommend physical
activity levels for adults (aged 19–64) [15] and older
adults (aged 65 and over) [16].
Experimental intervention
The rationale and development of the intervention has
been described elsewhere [17]. In brief, the intervention
is protocolised, with clear instructions on the selection,
prescription and progression of exercise, behavioural
elements and long-term physical activity promotion. The
exercise intervention will be delivered in groups of around
six to eight people, in suitable local venues such as leisure
centres or gyms, led by a physiotherapist, and if needed an
assistant. The physiotherapists and assistants will attend a
one-and-a-half-day training programme which covers all
elements of the intervention. Staff delivering the interven-
tion will also be issued with a manual describing it in detail.
A pre-exercise assessment will estimate each partici-
pant’s fitness using a 6-minute walk test [18], and infor-
mation on relevant co-morbidities and current exercise
will be collected at this time. The classes will comprise
aerobic exercise on static bicycles, and resistance exer-
cises using dumbbells and weighted belts and jackets.
The intensity of the aerobic exercise will be measured
using the Borg scale of rating of perceived exertion
(RPE) [19], modified for people with dementia [20]. The
intensity of the exercise will increase, with the intention
that by the final classes each participant should be work-
ing on the bicycle at low intensity (RPE = 2 [21]) for
5 minutes, and then at least at moderate (RPE = 4) inten-
sity for 20 minutes, with part of this at hard (RPE = 6)
intensity for those participants who are able; and in the
resistance exercises performing ten repetitions with the
ten repetition maximum weight, i.e. the heaviest weight
that can be lifted ten times with good form. Each class
will last approximately 1 hour, will be twice weekly with
at least one free day between classes, and each partici-
pant will be scheduled to attend 29 classes over approxi-
mately 4 months.
The intervention group will be encouraged to begin
some independent exercise whilst the exercise classes
are still taking place, supported by the use of a local ex-
ercise opportunities booklet detailing local facilities and
programmes, such as Exercise on Referral schemes and
Walking for Health groups. These participants will also
receive three phone calls and have one face-to-face
meeting with the physiotherapist in the 8 months fol-
lowing the exercise classes, to support and encourage
them to continue with independent exercise. Any par-
ticipants who withdraw from the intervention, either
during the exercise classes or the unsupervised exercise
period, will be encouraged to remain in the study and
complete the outcome measures at the 6-month and
12-month follow-up points.
Compliance with the intervention will be defined as
participants who have attended 75 % of the scheduled
exercise classes in the intervention arm.
Intervention fidelity checks
A quality control (QC) visit will be made by the local
intervention lead to the staff delivering the intervention
in the first few weeks of their exercise classes. This is
aimed principally at ensuring that the intervention is
being delivered in a standardised manner, and that the
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physiotherapist and exercise assistant can demonstrate
competency in all aspects of the intervention. The QC
assessor will also provide clinical supervision and sup-
port to the intervention staff as needed.
Items assessed will include: correct adherence to the
exercise procedures focusing on ensuring effective delivery
of an adequate exercise dose; correct completion of all
paperwork, especially the structured treatment forms
which record the exercise intensity and duration (enabling
accurate calculation of the exercise dose delivered); evi-
dence of the use of a person-centred care approach with
appropriate support given to participants; communication
between the staff regarding participants’ progress and
needs; and completion and return of adverse event docu-
mentation (where required). This visit will also provide
support and advice to staff to enhance their clinical com-
petencies and assist with smooth running of the exercise
group. A second QC visit will be made after some of the
formal behavioural support activities (such as goal setting)
have been commenced. If possible, these activities will be
observed, if this is not possible assessment will be via
inspection of the documentation and discussion with the
physiotherapist who carried out the activity, and correct-
ive guidance will be given as needed. The QC assessor will
also assess continued correct adherence to the exercise
procedures, with an emphasis on the use of progressions
and provision of adequate exercise challenges, and the
correct completion of clinical records.
At the end of each of these visits feedback will be pro-
vided to the staff, and further visits arranged if problems
are found in the QC assessment or if the staff need fur-
ther support. A QC form will be completed and signed
by both the assessor and the physiotherapist (provided
that the latter agrees with its findings).
Serious adverse event (SAE) and adverse event (AE)
reporting
An adverse event (AE) is defined as any untoward med-
ical occurrence in a participant which does not necessar-
ily have a causal relationship with this treatment. These
are most likely to be identified by the physiotherapist
during the exercise sessions, from information at the
sign-in, or after completion of the exercise sessions dur-
ing support telephone calls or the face-to-face meeting.
As each participant will have had a pre-exercise
assessment done, this will provide information on co-
morbidities. The DAPA trial population is likely to include
many participants over 70 years old and therefore com-
mon chronic diseases of older age will be anticipated, e.g.
osteoarthritis. It is expected that participants will experi-
ence some uncomfortable effects of participation in the
intervention, for example muscle or joint soreness in
response to exercise. Provided these follow an expected
pattern (e.g. as for delayed-onset muscle soreness), or need
simple modifications to the exercise activity (e.g. changes
to the bicycle seat height), or are non-serious exacerba-
tions of existing medical conditions, they should not be
considered as adverse events.
A serious adverse event (SAE) is an AE that fulfils one
or more of the following criteria:
1. Results in death;
2. Is immediately life-threatening;
3. Requires hospitalisation or prolongation of existing
hospitalisation;
4. Results in persistent or significant disability or
incapacity;
5. Requires medical intervention to prevent one of the
above.
SAEs to be reported in DAPA have been defined as
those that occur as the result of an incident during, or
within 2 hours of completing the exercise sessions or
follow-on physical activities. SAEs will be reported to
the Trial Co-ordinating Centre within 24 hours of the
physiotherapist becoming aware of them. The Trial Co-
ordinating Centre is responsible for reporting adverse
events to the sponsor and ethics committee within
required timelines.
The relationship of SAEs to trial treatment will be
assessed by the Chief Investigator and this will be re-
corded on the SAE form. All SAEs will be recorded in
the trial database, and where appropriate, reported to
and reviewed by the DMEC throughout the trial, and
will be followed up to resolution.
Data management and data checking
All data will be managed within the framework of the
Data Protection Act 1998 and the standard operating
procedures of WCTU. Data will be entered onto a be-
spoke application and will be stored on a secure WCTU
server with daily, weekly and monthly back-ups.
All case report forms (CRFs) and accompanying pa-
pers (excluding consent forms) are stored in a lockable
cabinet at WCTU in individual, numbered participant
files. The files are kept in numerical order and have re-
stricted access. Consent forms will be stored separately
as they contain identifiable information; the file will be
kept in a different cabinet to the CRFs. Intervention
forms are anonymised and stored in a lockable cabinet.
All data will be checked for completeness and validity
prior to data entry. Field researchers will be requested to
check data for completeness prior to returning the CRFs
to the DAPA trial team at WCTU. A further check will
be made by an appropriate member of the trial team and
queries clarified by the completing researcher prior to
data entry. Data will not be checked and entered by the
same trial personnel.
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A detailed Data Management Plan has been written
which provides full details of the management of the
data including the tracking and collection of data from
sites and participants, and guidance is provided for
telephone contact with participants and carers.
Statistics
Sample size
At the time of applying for research funding, our sample
size was based on the standardised Mini-Mental Status
Score [5] as the primary outcome measure. ISRCTN
registration was completed on 29 July 2011 at the same
time as the original ethical submission specifying the
sMMSE as the primary outcome. During the process of
developing the protocol, and with feedback from the
TSC and DMEC, we changed the primary outcome to
the ADAS-cog. We submitted this substantial amend-
ment to the protocol for ethical approval, and this was
granted on 17 July 2012. This was well in advance of the
first randomisation to the trial, which was undertaken
on 1 February 2013. The reasons for the change were
that the ADAS-cog is acknowledged to be more sensitive
in detecting cognitive change in individuals with mild to
moderate dementia than a variety of other measures,
including the sMMSE [22]. The ADAS-cog is able to
characterise different domains of cognitive performance
better than the other measures and has been recom-
mended by an expert task force as the cognitive out-
come measure of choice for research using participants
with moderate cognitive impairment [22]. Unlike many
other tests of cognition, the ADAS-cog has an expert-
agreed between-group mean difference of about 2 to 2.5
points [23, 24], although smaller differences can be worth-
while [7]. This means that we can use a valid but more
sensitive primary outcome measure. The potential sample
size efficiency using the ADAS-cog was substantial.
We specified the sample size parameters as follows.
We set the group difference of 2.45 ADAS-cog points.
Initially, we set the pooled standard deviation at baseline
at 6.3 ADAS-cog points based on a literature review
[25]. We checked the value of the pooled standard devi-
ation at baseline after 66 participants had been accrued
into the trial, and revised this to 7.8 ADAS-cog points.
There were no statistical or interim analyses undertaken
and hence no inflation of the sample size for interim
testing. We used 2:1 randomisation and made a small
upward adjustment for this [26] (p.144 equation 3.2).
This gives a sample size of 360 for alpha of 0.05 and a
power of 80 %. Recognising that there might be cluster-
ing associated with the group format of the intervention,
we inflated the sample using a design effect of 1.04
[intraclass correlation (ICC) = 0.01] in the intervention
arm, assuming that there will be five participants per
group (recognising that it may not be possible to achieve
and retain eight recruits to each group), giving a sample
size of 375. The sample size was further inflated to
account for 20 % loss to follow-up, of which 10 % will be
attributable to death. Thus a final sample size of 468
participants was set with 312 participants to be
randomly allocated to the intervention arm and 156
participants to the control arm.
As the ADAS-cog takes up to 35 minutes longer to
administer than the sMMSE, in order to reduce burden
on the participants and contain the costs of the trial, we
removed the Cornell Scale for Depression in Dementia
(CSDD) from the protocol. The ISCTRN registration
was updated with these amendments in December 2014.
Analyses
Data will be summarised and reported in accordance with
Consolidated Standards of Reporting Trials (CONSORT)
guidelines for randomised controlled trials [24], and we
will use intention-to-treat analyses as the primary analysis.
Hierarchical regression models will be used to estimate
the treatment effects (with 95 % confidence intervals), as
they allow us to account for the hierarchical data structure
i.e. participants nested within exercise groups. We will es-
timate the group effects in the trial by entering the group
variable into the hierarchical model as a random effect. If
the group effects estimate is negligible, then multiple
linear regression will be used to estimate treatment effects.
The models will adjust for those covariates (age, gender,
centre, and baseline ADAS-cog) which were considered to
be most important in the light of clinical input. In addition
we will estimate treatment effects over the 12-month time
period using longitudinal models. Prespecified subgroup
analyses looking at pre-randomisation variables of severity
of cognitive impairment (sMMSE ≥20 and <20), type of
dementia, physical performance and gender will be
conducted using formal tests of interaction [23].
At the beginning of each exercise class, the physiother-
apist sets aerobic exercise and resistance exercise targets
specific to each participant, and then marks at the end of
the class if the target was achieved. We refer to the targets
set for each participant as the prescribed dose. Dose
achieved will be described in two ways: (1) the percentage
of the DAPA physiotherapist prescribed minutes of
aerobic exercise at moderate intensity or harder that a
participant achieved over the course of the DAPA exercise
sessions, and (2) the percentage of the DAPA-prescribed
resistance exercise dose a participant achieved over the
course of the DAPA exercise sessions. For both definitions
of dose, we will investigate the association between
percentage prescribed dose achieved and the change in
cognition by observing a simple scatter plot and then
using linear regression models (unadjusted and adjusted).
This will not equate to a dose–response analysis, as the
dose has not been experimentally determined.
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Complier average causal effect (CACE) analysis will be
used to assess the effect of compliance with the interven-
tion on the primary outcome [27]. The primary analysis
will use participant-reported data. In the situations where
we have collected proxy data routinely, we will undertake
sensitivity analyses using these data.
The final anonymised data set will be accessible to all
study members after data lock. The Chief Investigator
will assume overall responsibility for the data report, and
will have full access to the trial data set. There are no
contractual agreements that limit access for investiga-
tors. The analysis plans described here will be finalised
and approved by the Trial Steering Committee and Data
Monitoring Committees prior to data lock.
Economic evaluation
The most significant formal costs associated with de-
mentia are the costs of social and long-term care [28].
Hospitalisation costs are also likely to occur, particularly
related to falls and injuries [29]. The economic evalu-
ation will therefore focus on the following major compo-
nents of costs: NHS primary and secondary care, local
authority care, the costs to other agencies or organisa-
tions, costs associated with institutional care and home
care support. Intervention costs will reflect the costs
necessary to implement the DAPA physical activity,
including development and training, overheads, equip-
ment, and staff-related expenses.
Two economic evaluations will be undertaken – first, a
within-trial evaluation, and second, a decision analytic-
based cost-effectiveness model. Both will be used to esti-
mate the expected incremental cost per quality-adjusted
life-year (QALY) gained for the DAPA interventions in
comparison to best practice usual care. For both analyses,
the primary perspective will be that of the UK NHS and
personal social services. The potential impact of adopting
a societal perspective on incremental cost-effectiveness
ratios will be tested in sensitivity analyses using data on
informal and indirect costs provided by carers at 6 and
12 months.
The within-trial analysis will compare the costs and out-
comes between the study arms at the end of follow-up.
The primary outcome measure will be the quality-adjusted
life-year (QALY). Health-related quality of life (HRQoL)
will be estimated using responses to the EuroQol EQ-5D
[10] obtained from participants and their carers (partici-
pant self-report, carer proxy report and carer self-report).
The primary analyses will be conducted using the EQ-5D
responses obtained from the participants. Nevertheless,
differences between participant and carer assessments of
participant HRQoL will be acknowledged through sensitiv-
ity analyses. Utility weights will be taken from the UK
General Population tariff for the EQ-5D [30, 31]. Unit
costs will be taken from national databases including the
NHS reference costs and the Personal Social Services
Research Unit (PSSRU) costs of health and social care.
Where national unit cost estimates are not available unit
costs will be estimated using established accounting
methods in consultation with NHS Trusts recruiting to the
study. In line with current recommendations for best
practice in economic analyses, costs and outcomes will be
discounted at 3.5 % per annum [32]. Probabilistic sensitiv-
ity analysis will be undertaken using the non-parametric
bootstrap. We will use the CSRI as a framework for
resource data capture [33].
The decision analytic cost-effectiveness analysis model
will use a lifetime time horizon to capture the full
impact of any mortality and health-related quality of life
differences on the long-term cost-effectiveness of the
exercise intervention. It is likely that the model will have
a semi-Markov structure to capture the time trend in
the underlying risk of mortality, health-related quality of
life, and costs of care. The methods for estimating
health-related quality of life and utility, unit costs and
discounting will be the same as for the within-trial
analysis.
Probabilistic sensitivity analyses will be undertaken
using Monte Carlo simulation techniques. The outputs
reported from the analysis will be the same as for the
within trial analysis.
Qualitative study
We will conduct a qualitative study in parallel to the
trial, the aim of which is to provide insight into partici-
pants’, carers’ and staff experiences of taking part in the
experimental intervention. Semi-structured interviews
with participants and carers and observations of the ex-
ercise classes will be carried out by a researcher trained
and experienced in qualitative research methodologies.
Observations will take place near the beginning, middle
and towards the end of the supervised part of the inter-
vention. We will conduct the interview study in two
sections. The first section will interview participants as
they experience the moderate to hard intensity training.
We will recruit a second, separate sample and interview
participants approximately 4 months after they have
finished the supervised part of the intervention.
It is possible that some participants may have problems
recalling their experiences. In those instances the focus of
the interview will be on their current experiences of exer-
cise. For those participants able to recall their experiences
of the supervised part of the intervention interviews will
seek to capture their experiences of taking part in both the
supervised and unsupervised parts of the intervention.
Current evidence suggests that doing research interviews
with people with cognitive impairments presents a number
of obstacles; these include short-term memory problems,
difficulties in abstract thinking and expressive language, a
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lack of insight and awareness of their diagnosis, and dam-
age to their sense-of-self related to their experiences of
diagnosis and symptoms of dementia [34]. It is suggested
that obstacles may be overcome by the interviewer adopt-
ing an attitude that assumes the person with dementia has
something valuable to say, by listening carefully, accepting
the interviewee as they are and with an openness to under-
stand them. The deployment of strategies to minimise or
overcome dementia-related obstacles include: taking a
case-specific approach by taking the time to meet inter-
viewees before the formal interview in order to build
rapport and gauge expressive skills, being comfortable with
long pauses and the expression of strong emotions,
avoiding the use of complex concepts and adjusting the
language to align with participants’ language, use of photo-
graphs as a memory aid and use of direct interview styles
where expressive skills are very limited [34, 35]. The
researcher undertaking the interviews has experience and
training around these issues.
Interviews with carers will include a focus on partici-
pants’ and carers’ experiences of taking part in the super-
vised and unsupervised parts of the intervention and their
experiences of living with dementia. We will interview
participants until we feel confident that we have reached
data saturation. Based on our previous experiences we
anticipate that we will interview approximately 20 partici-
pants and their carers. Sampling will be purposive and will
be aimed at reflecting the population of the intervention
arm of the trial in relation to gender, ethnicity and social
class. Pseudonyms will be used and any other identifying
information will be anonymised to ensure participants’
confidentiality is maintained. Interview transcripts
and field notes will be uploaded into NVivo (QSR
International Pty Ltd, Melbourne, Australia), a com-
puter program for qualitative data, to assist with data
management and analysis.
Our approach to data analysis will be thematic and
will broadly follow the principles of grounded theory
[36]. This requires a constant moving back and forth
within and across field notes and transcripts and starts
from the first interview and continues throughout the
data collection period and beyond. A thematic analysis
involves identifying, describing, analysing, interpreting
and reporting repeated patterns or themes and categories
within participants’ transcripts using a deductive and in-
ductive approach. A theme captures important meanings
across participants in relation to the research question and
represents some level of patterned response or meaning
across a data set and the relevant research literature [37].
Transcripts will be analysed by the researcher carrying out
the interviews and, to ensure rigorous analysis, a second
senior researcher will independently analyse approximately
20 % of the transcripts [37]. These two researchers will
meet to discuss the differences and similarities between the
transcripts and their own interpretations of them will be
explored. Discussion of the analytic process and its findings
will be shared within the wider research team thereby
enabling an opportunity for critical reflection and further
analytic refinement. Disagreements regarding the
identification, description, analysis or interpretation of
themes will be resolved through discussion and if
necessary further analysis.
Discussion
Dementia becomes increasingly prevalent with increasing
age. As the population in developed countries ages, it is
probable that the number of people in that population
with dementia will increase. Treatment options for people
with mild to moderate dementia are limited, and physical
activity or exercise has been shown to have some effects
on cognition.
The DAPA study will be the first large, randomised
trial of the cognitive effects of exercise on people with
dementia. The intervention is designed to be capable of
being delivered within the constraints of NHS service
provision, and the economic evaluation will allow assess-
ment of its cost-effectiveness. Results will be published
in an appropriate peer-reviewed journal.
Trial status
At the time of submission for publication, the DAPA
trial was still recruiting participants.
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